LB Pharmaceuticals, Inc. (LBRX)
48.80
+0.59
(+1.22%)
USD |
NASDAQ |
Aug 25, 16:00
48.78
-0.02
(-0.04%)
After-Hours: 19:59
LB Pharmaceuticals Net Income (Quarterly) : -51.60M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -51.60M |
| March 31, 2026 | -19.05M |
| December 31, 2025 | -11.47M |
| September 30, 2025 | -3.556M |
| June 30, 2025 | -4.871M |
| March 31, 2025 | -5.306M |
| Date | Value |
|---|---|
| December 31, 2024 | -5.071M |
| September 30, 2024 | -14.18M |
| June 30, 2024 | -27.70M |
| March 31, 2024 | -16.15M |
| March 31, 2023 | -3.341M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 48.51M |
| Neumora Therapeutics, Inc. | -43.08M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 51.60M |
| EPS Diluted (Quarterly) | -1.712 |
| Enterprise Value | 1.077B |
| Earnings Yield | -6.11% |
| Normalized Earnings Yield | -6.120 |